NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review
| Autor: | Lucas C. Quarantini, Rodrigo Simonini Delfino, Fernanda S. Correia-Melo, Igor D. Bandeira, José Alberto Del-Porto, Lucas Braziliano, Juliana Surjan, Acioly L.T. Lacerda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Neurology business.industry Public Health Environmental and Occupational Health medicine.disease 030227 psychiatry 03 medical and health sciences Behavioral Neuroscience Glutamatergic Esketamine 0302 clinical medicine Mood disorders Tolerability medicine NMDA receptor Antidepressant Bipolar disorder business Neuroscience 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Current Behavioral Neuroscience Reports. 7:76-85 |
| ISSN: | 2196-2979 |
| DOI: | 10.1007/s40473-020-00201-w |
| Popis: | This manuscript aims to review the role of NMDA antagonists in the treatment of mood disorders, more specifically in bipolar disorder. Different sources of evidence have implicated glutamatergic abnormalities in the pathophysiology of bipolar disorder. In particular, rapid and robust antidepressant effects of NMDA antagonist ketamine and its enantiomer esketamine have been consistently reported by several controlled trials. In last years, considerable research efforts have been destined to identify glutamatergic drugs with a better safety and tolerability profile. However, efforts to develop “ideal” glutamatergic antidepressant have proven challenging. Considering several glutamatergic targets with promising findings in the treatment of mood disorders and innumerous mechanisms of action associated, NMDA antagonists have been raised as the subclass of glutamatergic agents with the most robust evidence. Among them, the agents classified as “broad glutamatergic modulators” such as ketamine and esketamine appear to be the most promising among NMDA antagonists. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink